Therapeutic advances in gastroenterology · 2026
Association of nutritional indices with early clinical remission in patients with moderate-to-severe ulcerative colitis treated with vedolizumab.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Hao, Wang Yueyuan, Wu Jun, Wang Hongying, Min Congcong, Meng Pin, Liu Hua, Mao Tao, Xu Yonghong, Jin Lixin, Wang Baihui, Han Xiaonan, Liu Ailing, Ding Xueli
Аннотация
BACKGROUND: The relationship between nutritional indices and treatment response in ulcerative colitis (UC) remains poorly characterized.
OBJECTIVES: To assess the discriminatory ability of Geriatric Nutritional Risk Index (GNRI), Malnutrition Universal Screening Tool (MUST), and Prognostic Nutritional Index (PNI) in evaluating the clinical efficacy of vedolizumab (VDZ) in patients with moderate-to-severe UC.
DESIGN: A retrospective multicenter study.
METHODS: This study enrolled moderate-to-severe UC patients receiving VDZ at three centers in northern China from 2021 to 2025. The relationship between baseline nutritional indices and clinical remission, alongside conventional biomarkers, was analyzed. Discriminatory performance was evaluated using receiver operating characteristic curves and area under the curve (AUC) analysis.
RESULTS: A total of 184 patients were included. At week 14, multivariable logistic regression identified GNRI, PNI and MUST as factors significantly associated with clinical remission. GNRI showed the strongest correlation with clinical remission (r=0.340, p<0.001), followed by HGB (r=0.316, p<0.001), PNI (r=0.308, p<0.001), PLR (r=-0.271, p<0.001), MUST (r=-0.216, p=0.003), and NLR (r=-0.163, p=0.027). GNRI had the highest AUC (0.697), followed by HGB (0.683), PNI (0.678), Alb (0.660), PLR (0.657) and MUST (0.614). GNRI exhibited significantly greater discriminatory ability for 14-week clinical remission than Alb (p=0.018) and MUST (p=0.041). No significant differences in diagnostic accuracy were found between GNRI, HGB, PNI, PLR, and NLR (p>0.05). At week 30 and 54, multivariate analysis showed that only baseline HGB remained independently associated with remission.
CONCLUSIONS: Patients with lower nutritional risk-as reflected by higher GNRI and PNI scores, alongside lower MUST scores-were significantly more likely to achieve clinical remission at week 14.
OBJECTIVES: To assess the discriminatory ability of Geriatric Nutritional Risk Index (GNRI), Malnutrition Universal Screening Tool (MUST), and Prognostic Nutritional Index (PNI) in evaluating the clinical efficacy of vedolizumab (VDZ) in patients with moderate-to-severe UC.
DESIGN: A retrospective multicenter study.
METHODS: This study enrolled moderate-to-severe UC patients receiving VDZ at three centers in northern China from 2021 to 2025. The relationship between baseline nutritional indices and clinical remission, alongside conventional biomarkers, was analyzed. Discriminatory performance was evaluated using receiver operating characteristic curves and area under the curve (AUC) analysis.
RESULTS: A total of 184 patients were included. At week 14, multivariable logistic regression identified GNRI, PNI and MUST as factors significantly associated with clinical remission. GNRI showed the strongest correlation with clinical remission (r=0.340, p<0.001), followed by HGB (r=0.316, p<0.001), PNI (r=0.308, p<0.001), PLR (r=-0.271, p<0.001), MUST (r=-0.216, p=0.003), and NLR (r=-0.163, p=0.027). GNRI had the highest AUC (0.697), followed by HGB (0.683), PNI (0.678), Alb (0.660), PLR (0.657) and MUST (0.614). GNRI exhibited significantly greater discriminatory ability for 14-week clinical remission than Alb (p=0.018) and MUST (p=0.041). No significant differences in diagnostic accuracy were found between GNRI, HGB, PNI, PLR, and NLR (p>0.05). At week 30 and 54, multivariate analysis showed that only baseline HGB remained independently associated with remission.
CONCLUSIONS: Patients with lower nutritional risk-as reflected by higher GNRI and PNI scores, alongside lower MUST scores-were significantly more likely to achieve clinical remission at week 14.